01—Abstract
Summary
Summary of the 8-K filed September 21, 2023. Cited figures are marked; the original filing is the authoritative source.
CME Group Inc. (CME) filed an 8-K on September 21, 2023, to disclose changes to its Clearing House's collateral fee schedule.
These changes were communicated to Clearing Member Firms via Advisory Notice 23-290 and are scheduled to take effect on January 2, 2024. While the specific details of the fee adjustments are not provided in this 8-K, the market will be monitoring the impact of these changes on clearing member costs and CME's revenue, particularly as the effective date approaches. Investors should note that this disclosure is made under Regulation FD and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
02—Key points
Key Highlights
- CME Group announced upcoming changes to its Clearing House collateral fee schedule.
- The fee adjustments are effective January 2, 2024.
- The information was communicated to Clearing Member Firms via Advisory Notice 23-290.
- The advisory notice has been posted on CME Group's website.
- This filing is a Regulation FD disclosure, meaning the information is made public to avoid selective disclosure.
- The disclosure is not deemed 'filed' for the purposes of Section 18 of the Exchange Act, limiting liability associated with this specific disclosure.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to publicly disclose that CME Group Inc. has communicated changes to its Clearing House collateral fee schedule to its Clearing Member Firms. This ensures transparency and compliance with Regulation FD.
When will the new collateral fee schedule take effect?
The changes to the collateral fee schedule are effective as of January 2, 2024.
Where can investors find more details about the collateral fee changes?
While the 8-K filing itself does not contain the specific details of the fee changes, it states that Advisory Notice 23-290, which outlines these changes, has been posted to CME Group's website. Investors should look for this advisory notice on the company's investor relations or corporate website.
Does this filing have any implications for CME Group's financial reporting or legal liability?
This filing is made under Regulation FD and is specifically stated as not being 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it's primarily for disclosure and does not carry the same legal liabilities as a regular filing under that section. However, the changes themselves could indirectly impact future financial performance.
04—Continue